This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk06: good afternoon ladies and gentlemen and welcome to the zynex third quarter 2023 earnings conference call at this time all participants are in a listen only mode should you need assistance please signal a conference specialist by pressing star then zero on your telephone keypad a question and answer session will follow the formal presentation as a reminder this conference is being recorded i would now like to turn the conference over to quinn Kalanen from MZ North America.
spk07: Thank you, Operator, and good afternoon, everyone. Earlier today, Zynex released financial results for the third quarter ending September 30, 2023. A copy of the press release is available on the company's website. Joining me on today's call are Thomas Sangard, Chairman, President, and Chief Executive Officer, Dan Moorhead, Chief Financial Officer, Anna Lusak, Chief Operating Officer, and Donald Gregg. President of Zynex Monitoring Solutions. Before we begin, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including without limitation the company's 2022 Form 10-K and subsequent Form 10-Qs, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development, product potential, the regulatory environment, sales and marketing strategies, capital resources, or operating performance. With that, I'll now turn the call over to Thomas.
spk02: Thanks, Quinn, and good afternoon, everyone. Thank you for joining us today for our third quarter 2023 earnings call. The third quarter was highlighted by ongoing revenue momentum, leading us to our 10th consecutive quarter of profitability and six-quarter record high order numbers. We once again received the highest number of prescriptions in the company's history, beating our previous record and celebrated our one millionth patient treated since our founder, Sinex. These records led to total revenue for the quarter of $49.9 million, a 20% increase over the same period in 2022, and we produced 10 cents of earnings per diluted share. Our sales force continues to increase productivity and grow orders significantly each quarter, a testament to a great sales force, leadership, and great products. Orders increased 39% year-over-year, and we believe that there is considerable runway for us to continue growing orders into the future. The results we continue to show and the good work we are doing toward reducing the impact opioids have on communities are beginning to be recognized by the broader community, with the latest example being our ranking as the 23rd amongst the top 100 healthcare companies according to the Healthcare Technology Report. To help drive our growth, we introduced three new rehabilitation products in the third quarters. building on our holistic, non-invasive approach to pain management. The new products include Sinex Pro-Cerastic Lumbar Sacral Orthosis, or TLSO, a dual-purpose back brace for the mid and lower spine, Sinex Pro-Wrist, a wrist brace for a broad spectrum of wrist-related pain management, including carpal tunnel syndrome, and the Sinex CryoHeat, a localized cold or hot fluid therapy system for home or hospital use. We continue to focus on profitable growth by adding products to our portfolio in a complementary way that combine with our industry leading prescription strength pain management device, the NexWave. In addition to the impressive results from our profitable pain management division, CMS, or Sinix Monitoring Solutions, continue to move forward in the third quarter in the development of our blood and fluid monitor and our laser-based pulse oximeter, or co-oximeter. We were excited to announce FDA clearance earlier this year for our second-generation blood and fluid volume monitor, an invasive wireless technology targeted to improve patient outcomes with better fluid management in hospital settings. We continue to collect additional data in clinical trials, and Don Gregg will provide further updates on this product in his prepared remarks. We have three additional products in the pipeline in our hospital monitoring division. A laser-based pulse oximeter, NICO is the trade name for it, a monitor for early detection of sepsis, and a non-invasive laser-based monitor of total hemoglobin levels, the HEMOX. Overall, we are making great progress in the patient monitoring division, which we believe will have a game-changing growth potential for the company. Looking ahead, we are making significant progress building on our holistic, non-invasive approach with at-home pain management devices and diversifying with new products. We are rapidly expanding direct sales that is delivering accelerating and high recurring revenue as we continue to execute operationally and strategically. In tandem, we are focused on ramping up our hospital monitoring division, which represents a large and growing market opportunity. We expect consistent growth and strong financial performance for the remainder of 2023, following the double-digit growth we have produced year after year. We also expect an additional catalyst and regulatory milestones in 2023 as we work to execute on our strong pipeline of new products. We look forward to additional updates in the months to come as we build our sales force and execute on growth objectives to improve the quality of life of patients suffering from debilitating pain or illnesses and bring long-term value for our shareholders. With that, I'll turn the call over to Anna Lukczak, our Chief Operating Officer, for a more detailed business update on the Pain Management Division.
spk01: Anna Lukczak Thank you, Thomas. Zynex's Pain Management Division had another impressive quarter marked by a sequential increase in order volumes over the second quarter and a 20% year-over-year increase in revenues. We were also incredibly proud to have surpassed treating one million patients during the quarter. Reaching such a tremendous landmark for the company is a testament of the tireless efforts and teamwork that each of our employees brings to this company. As Thomas mentioned, we also added three new products during the quarter. Expanding our pain management product line helps us diversify our revenue streams and provides our sales force with more opportunities to break into new prescribers. We've seen continuous increase in volumes of our distributed products, including strong initial volumes of TLSO, wrist braces, and CryoHeat. The key to growth in pain management is the continued build-out of our sales force. We ended the third quarter with approximately 480 sales reps. During 2023, we've added a net of approximately 50 sales reps, and as we've mentioned previously, we continue to be aggressive in off-boarding reps who are underperforming, so our overall rep growth has been a little slower than normal. Revenue per rep on an annualized basis was approximately $430,000 during Q3, which is up 10% from Q2. As a reminder, it takes approximately three years for reps to meet our $1 million target in annual sales. The average tenure across the sales force is currently under 18 months, so we're still on track with that metric. We continue to make improvements in evaluating potential sales reps and evaluating productivity of new reps, which has allowed us to maintain revenue per rep at a high level despite the large numbers of reps we're adding. We're ultimately working to fill out our 800 sales territories and continue to improve our processes to do so in a profitable manner. We expect that by the end of the year we should reach roughly 500 sales reps. I look forward to another profitable year for the Pay Management Division in updating you all on our market expansion and future calls. I'll now ask Don Gregg, President of Xynex Monitoring Solutions, to provide updates related to that business division.
spk04: Thank you, Anna. Our patient monitoring division is a long-term investment for Xynex to diversify our revenues into one of the world's largest medical technology companies. Our pain management division's tremendous growth and profitability allow us to self-fund the build-out of a world-class patient monitoring business that leverages industry-transforming technologies developed through acquisition and organic development. We can build the monitoring division while maintaining profitability and positive cash flow. Xynax participated in the American Society of Anesthesiologists conference in October. Developing familiarity with our technology's capabilities amongst physicians is critical as we prepare for the launch of our monitoring products. From the ASA conference, we gathered several hundred leads, met with many key opinion leaders, continued to conduct market research, and presented the underlying science and benefits of our laser pulse oximetry technology to this critical anesthesia group. Attendance at this conference and others have indicated strong demand for our monitoring products and revealed several unforeseen potential sources of demand amongst non-core customers. Xynex will continue to be active in similar venues in the future that allow us to present our technologies to key opinion leaders. We continue to develop NICO, our laser-based pulse oximeter, for commercialization in 2024. We continue to work toward FDA submission with several clinical trials. The clinical work has reinforced our confidence in NICO and the benefit it will provide to clinicians and patients. We've continued to prepare patent submissions to the USPTO and have continued revising our commercialization and marketing launch plan accordingly. Our next generation non-invasive CM blood and fluid monitor continues to advance positively. Having received FDA clearance for the CM1600 last quarter sets up our next generation CM device, meeting our R&D and clinical milestones nicely for a smooth entry into the market. The CM monitoring technology is an entirely new addition to operating rooms, so market uptake will likely follow an elongated trajectory and rely on extensive engagement with medical advisors, key opinion leaders, and industry audiences to build momentum. I will now turn the call over to Dan Moorhead, Chief Financial Officer, for a more in-depth look at financial performance for the quarter.
spk05: Thanks, Don. Please refer to our press release issued earlier today for a summary of our financial results for the third quarter of 2023. After commenting on our financial results, Thomas will review our guidance for the fourth quarter of 2023. In the third quarter, orders grew 39% year-over-year to the highest number of orders in company history for the sixth consecutive quarter. Net revenue grew 20% to $49.9 million from $41.5 million in 2022, primarily related to the growth in device orders. Device revenue increased 49% to $16.9 million compared to $11.3 million in the third quarter last year. Supplies revenue increased 10% year over year to $33.1 million from $30.2 million in the third quarter last year. Gross profit in the third quarter increased to $40.4 million or 81% of revenue as compared to $33.1 million or 80% of revenue in 2022. Sales and marketing expenses were $22.1 million in the third quarter of 2023, compared to $17.2 million in the same period in 2022, primarily due to increased headcount of our sales force and increased incentive compensation related to order growth. G&A expenses were $12.7 million in the third quarter of 2023, compared to $9.4 million last year. Approximately 10% of the increase in G&A is related to investments in our monitoring solutions division and related headcount to launch our new products. The remainder is primarily for back office headcount related to order growth. Tax expense as a percentage was 27% effective rate for the quarter. Net income was $3.6 million and produced 10 cents per basic and diluted share in the third quarter of 2023, compared to $4.9 million or 13 cents per basic and diluted share in 2022. Adjusted EBITDA for the three months ended September 30th, 2023 was 7.3 million versus 8.1 million in the quarter ended September 30th, 2022. We ended the quarter with $52.4 million in cash and cash equivalents and short-term investments and working capital of 83.1 million. Cash flows from operations for the three months ended September 30th, 2023 was a record 8.9 million. And for the nine months cash from operations increased 29% year over year to 11.6 million. In the third quarter, we continued our stock buyback and repurchase 14.9 million of common stock bringing the total repurchases in the past 18 months to 51 million. As we've stated before, We believe this to be a signal to our shareholders that we are incredibly confident in our management team, the growth opportunities for both divisions, and we remain committed to creating shareholder value in the near and long term. With that, I'll turn the call back over to Thomas.
spk02: Thank you, Dan. It is becoming increasingly evident that we still have a long runway in our pain management division, growing revenues from the current just below $200 million to $800 million over the next few years with a strong bottom line. We have the monitoring division on the brink of launching not just one, but four game-changing product lines. And Sinix continues to operate on the backdrop of a strong balance sheet. We've had a strong start to Q4 in terms of orders and expect to post our seventh consecutive record quarter. With the continued growth in orders in the fourth quarter of 2023, we expect total revenue of 52.5 to 57.5 million, which is approximately 13% greater than the fourth quarter of 2022, and diluted earnings per share of 17 to 22 cents. As for our 20-fold earnings, 2023 outlook, we are reiterating our initial guidance and expect total revenue to be 189.5 to 194.5 million, representing growth of approximately 20% over 2022, and diluted earnings per share of 40 to 45 cents. With that, operator, please open up the call for questions.
spk06: We will now begin the question and answer session. To ask a question, you may press star then 1 on your telephone keypad. If you're using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star then 2. At this time, we will pause momentarily to assemble our roster. The first question comes from Jeffrey Cohen with Ladenburg-Fallman. Please go ahead.
spk03: Good afternoon. How is everyone? Great. We're doing pretty good.
spk02: Jeff, how are you?
spk03: Pretty good. Thanks for taking the question. So just a few. So I wondered if you could drill in a little bit on the devices versus supplies. Have you seen a lag effect, if you will, on supplies behind devices historically, and should we assume that the stronger side of devices gets further pulled through on the supply side?
spk02: No, I think Dan can obviously give you a little more technical detail, but overall, when we're here for several months, have had a very strong growth in orders a lot of the revenue on the initial claims that is paid by insurance companies, a lot of that is obviously devices. And the supplies is revenue that typically sits on the tail end of those orders. So with the current up ticket orders, We typically see a lot of device revenue, and as a percentage, not in absolute numbers, but as a percentage, we see a little less on supplies. But I don't know if you have anything more technical to say there, then.
spk05: Yeah, no, I agree with you. I think, you know, if you do look, advice usually gets a little stronger as compared to supplies as the year goes on. And so that's just kind of a general trend we have. And I would agree with Thomas, the strong order growth is driving that number. So, you know, maybe instead of 25.75 going forward, it's more of a 30.70, just because the order growth has been so strong. But again, both are growing well.
spk02: Yeah, long-term, you'll see that percentage for supplies. Supplies creep up again.
spk03: Okay. Got it. Next, could you talk a little bit about some of the distribution channels that the physical therapy offerings are going through and how those channels may have changed over the past few quarters and what they may look like going forward?
spk02: Maybe that's one for you.
spk01: There's no significant changes that we've seen over the last few quarters. It's still the same channels that are producing our prescriptions and orders.
spk03: Got it. And then lastly for us on the buyback front, I think you talked about $51 million over 18 months. So was the last piece of $10 million concluded and now you're on to the sixth one versus the fifth one?
spk02: Not yet. It's obviously something considering how well we are doing organically, how strong our balance sheet is. We here recently have primarily been investing in two areas, the monitoring division and also because of how inexpensive the stock is right now. We find good use of the capital by buying back stock. And considering how it sits right now, we've we are actively debating to deploy more of our cash to buy back stuff.
spk05: So the fifth, there's been five recently, Jeff. The fifth one finished in October, so it wasn't quite done at September 30th when you look at it, but that last $10 million finished up in October.
spk03: Okay. Perfect. Professor Frost, thanks for taking the questions, and congrats on a strong readout. Thank you. Thank you. Thank you.
spk06: The next question comes from Shagun Singh with RBC. Please go ahead.
spk00: Great. Thank you so much for taking the question. So I was hoping you could elaborate a little bit more on the revenue momentum you're seeing. You know, you indicated the highest level of orders in the company's history. You know, can you provide some color on what is driving that? Is it new? Is it existing accounts? You know, is it adding more sales reps and regions? And then on the order growth, it grew about 39% year-over-year, which was higher than the sales growth of 20%. So just what are the implications of that, and how should we think about it as a predictor of future sales?
spk02: Net-net, our sales force is becoming more productive. We keep adding more sales reps. However, we also... proactively not letting sales reps that may not produce as much as we'd like to see long-term and doesn't seem to have a potential to get there. So overall, we continue to see a higher productivity in our sales force as we get better and better at hiring new talent. So the audit growth comes from that. It's also, relatively speaking, been... been very strong here for a number of months compared to last year. A year and a half, two years ago, our order growth was more in the single digits. And therefore, when we get some momentum in terms of the order growth, it turns into some very high percentages. The average order growth, if you look at the last two to three years, is more in the just over 25%, a little less than 30%, if you look at that on an annual basis, which correlate pretty well with our revenue growth. There's still a little bit to come there. We expect the full year to come in at 20%. revenue growth and we expect with the orders we're getting now and the revenue that will generate for many quarters to come that we have strong revenue growth still in the pipeline that's already landed on the books in terms of prescriptions that now needs to get built and battling with insurance companies to get paid, etc. That's those things will be executed here over the next many quarters for the orders that we recently received. So there's always a lag there between when we have a growth spurt in orders and when revenue catches up to that.
spk00: Got it. That's really helpful. And then I was wondering if you could maybe share some directional outlook for 2024 you know, as it relates to your pain management business is plus 20%, you know, growth achievable next year. It seems like that's somewhat of a base case given how you're tracking this year. And then on the patient monitoring side, you know, just contribution from the CM1600 and anything we should factor in for NICO. And any color on the OPEX side would be great, too. Thank you for taking the questions.
spk02: Yes, I think in terms of the pain management business, we are tentatively looking at growth a little over 20%. So somewhere in the range of 20% to 25% is probably a good guess for how we're going to fare in terms of order and revenue growth next year in that division. We'll probably be, because we expect a lot of the activity in terms of additional data collecting and also be dealing with the FDA to take place in the first half, of 2024 for the NICO and see 1600 and further generations of that. We expect that. So we will be lucky to see some revenue in the second half of next year.
spk05: And then, Shagun, as far as on the profitability side, I think this year we're kind of in the flattest range. I think next year we would expect to be up, you know, at least 10% somewhere in that range on the EPS side as we leverage some of the investments we've made. But right now, you know, I think the ZMS contribution on the revenue side is probably immaterial. Yeah.
spk00: Got it. Thank you for taking the question.
spk06: Thank you. The next question comes from Yi Chen with HC Wainwright. Please go ahead.
spk08: Thank you for taking my questions. Could you comment on the three new products for pain management in terms of the origin of the products, whether they are prescription products, and how these products are used in connection with NextWave? Thank you.
spk01: Yes, absolutely. So the three new products that we added, the TLSO, cryoheat, hot and cold therapy, and the wrist brace are Zynex private labeled devices. They are all prescription only, and they fall within our pain management line and complement our flagship Next Wave device, and they're frequently prescribed together. So they fall within, essentially what we're trying to accomplish is become a one-stop shop for non-invasive, non-addictive pain management solutions for prescribers looking for that. Okay.
spk08: So the reported 39% auto growth for the third quarter, does that include those three products as well?
spk01: Yes.
spk08: So going forward, your reported auto growth will include those three products, correct? Correct.
spk05: Correct. Correct, but they've always included, you know, we distribute a number of products. These are three new products, and those distributed products have always been included in order growth, so it's pretty consistent with what we've done in the past. Okay.
spk02: Yeah, a prescription is a prescription, and whether it's low back support or, in some cases, same patient gets two prescriptions, and they get paid independently by insurance companies. A good example is the cryoheat, which the cold portion of that is really fantastic to use along with the next wave right after and immediately after orthopedic surgery. So that would be an example. We'd get two prescriptions, same patient, and it would be two billing lines that insurance companies pay separately for.
spk08: Could you give us a rough estimate as to the percentage of revenue represented by these three new products as a percentage of the total revenue in the third quarter?
spk05: The distributed products are about 15% of our device revenue.
spk08: Okay. And they have a similar gross margin compared to the next one?
spk02: Yes, it's similar. Pretty much the same. Else, we wouldn't take them on.
spk08: Okay. Thank you.
spk06: This concludes our question and answer session. I would like to turn the conference back over to Thomas Zengard for any closing remarks.
spk02: Thank you for joining us today. We are pleased with our performance this quarter and the consistent growth our team is delivering. We look forward to leveraging that momentum throughout the rest of the year and speaking to you at upcoming investor events. We appreciate your time and interest in signings. Have a great day.
spk06: The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.
Disclaimer